Kidney disease affects millions of Americans, with Black communities facing disproportionately higher risks due to genetic factors, socioeconomic challenges, ...

“Our data suggest SGLT2 inhibition as a safe strategy to prevent kidney stone recurrence in patients with kidney stones ,” Dr Fuster’s team concluded. Other study findings indicate the empagliflozin ...

The Food and Drug Administration has approved Ozempic ® (semaglutide) to reduce the risk of sustained estimated glomerular ...

The approval is based on results from the Phase III FLOW trial demonstrating Ozempic reduced the risk of severe kidney outcomes by 24% compared to placebo, including kidney failure, reduction in ...

The latest semaglutide (Ozempic; Novo Nordisk) approval is set to tackle a major need for patients with both type 2 diabetes ...

Ozempic, the drug that was originally approved to treat type 2 diabetes, has now also been approved by the FDA to reduce ...

Veteran Leader Brings Extensive Expertise in Rare Disease, including Renal Disease, and a Track Record of Regulatory Success with Orphan Diseases and Breakthrough Therapy DesignationsCAMBRIDGE, Mass., ...

Many older people develop chronic kidney disease and are also likely to be on cholesterol-lowering drugs known as statins.

Statins, a class of cholesterol-lowering drugs, have no effect on kidney function, a research team led by the University of Iowa has found.

Statins, a class of cholesterol-lowering drugs, have no effect on kidney function, a research team led by the University of ...

In line with trial results, real-world data suggest GLP-1 receptor agonists have certain benefits in patients with moderate to severe chronic kidney disease (CKD).